Clinical Trials Logo

Clinical Trial Summary

Preeclampsia is commonly viewed as one of the hypertensive pregnancy disorders, which cover a spectrum of clinical presentations from chronic hypertension ( hypertension occurring prior to 20 weeks of gestation) and gestational hypertension (hypertension occurring after 20 weeks of gestation) To more severe forms, including preeclampsia, eclampsia (its convulsive form), and HELLP syndrome (hemolysis, elevated liver enzyme S, and low platelets)


Clinical Trial Description

Treatment for patients who have developed preeclampsia or eclampsia mainly consists of control of hypertension, magnesium sulphate for prevention of eclampsia and convulsions, and planning for delivery.

Magnesium sulfate has been used to prevent eclamptic convulsion since 1925, its efficacy was confirmed by a large randomized controlled trial in 2002. Eclampsia could be prevented in more than 50% after magnesium sulfate administration . The World Health Organization recommended magnesium sulfate as the most effective, safe, and low-cost drug for the prevention of seizure in severe preeclampsia and eclampsia . The recommended dose of magnesium sulfate is 4 to 6 gram intravenous loading dose, followed by maintenance intravenous drip at the rate of 1 to 2 gram per hour .

Although different magnesium sulfate regimens have been tested, two dosing regimens are internationally recommended and widely used. The Pritchard regimen is a predominantly intramuscular regimen given as a loading dose of 4 g intravenously , and 5 g Intramuscular into each buttock followed by a maintenance dose of 5 g Intramuscular every 4 hours. This regimen is popular in resource-limited settings where intravenously administration of magnesium sulfate may not be feasible. However, it is associated with pain and a higher risk of infection at the injection site.

The Zuspan regimen is given as a 4 gram intravenously loading dose followed by continuous intravenously infusion of 1 gram per hour.

Either 1 gram or 2 gram maintenance dose of Magnesium Sulphate has been reported to reduce the development of eclampsia. Randomized controlled trials offering direct comparison between these 2 doses are lacking. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03164304
Study type Interventional
Source Assiut University
Contact
Status Completed
Phase Phase 4
Start date May 30, 2017
Completion date January 30, 2020

See also
  Status Clinical Trial Phase
Terminated NCT04725812 - Complement Regulation to Undo Systemic Harm in Preeclampsia Phase 2
Active, not recruiting NCT03744988 - Serum Androgen Levels as a Marker for the Severity of Preeclampsia
Completed NCT02189148 - First-trimester Prediction of Preeclampsia
Completed NCT04058405 - Risk Prediction Models for Adverse Maternal and Neonatal Outcomes in Preeclampsia
Not yet recruiting NCT06265415 - Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine N/A
Completed NCT02379832 - Pre-Eclampsia And Growth Restriction: a Longitudinal Study
Not yet recruiting NCT01538121 - Antiphospholipid Antibodies and Early Severe Preeclampsia. N/A
Recruiting NCT01906567 - İs There a Relationship Between Severity of Preeclampsia and Maternal Heavy Metal Levels? N/A
Recruiting NCT01382732 - Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia Phase 3
Completed NCT01408979 - Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia Phase 4
Completed NCT01538147 - Restless Leg Syndrome and Severe Preeclampsia N/A
Terminated NCT03008616 - Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia Phase 2/Phase 3